1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,350 | 9,950 | 16:53 | |
| 9,350 | 9,950 | 16:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:36 | MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | 151 | GlobeNewswire (Europe) | Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failure Study initiates in Lviv, Ukraine... ► Artikel lesen | |
| Di | MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 | 1 | GlobeNewswire (USA) | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs | 2 | GlobeNewswire (USA) | ||
| 17.04. | MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer | 168 | GlobeNewswire (Europe) | First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset... ► Artikel lesen | |
| 03.04. | MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 02.04. | MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy | 3 | GlobeNewswire (USA) | ||
| 31.03. | MiNK Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12 | 6 | Seeking Alpha | ||
| 31.03. | MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | 207 | GlobeNewswire (Europe) | ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000-300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing... ► Artikel lesen | |
| 27.03. | MiNK Therapeutics: Aktie springt nach Klarstellung zu Gesprächen über Kombinationsstudien | 8 | Investing.com Deutsch | ||
| 27.03. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | MiNK Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 17.03. | MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs | 1 | GlobeNewswire (USA) | ||
| 11.03. | Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? | 7 | Benzinga.com | ||
| 10.03. | MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally | 2 | Benzinga.com | ||
| 10.03. | Morning Market Movers: MiNK Therapeutics, Garden Stage, Arq, Inc., SciSparc See Big Swings | 660 | AFX News | BEIJING (dpa-AFX) - At 8:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 10.03. | MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers | 6 | Seeking Alpha | ||
| 10.03. | MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers | 4 | GlobeNewswire (USA) | ||
| 04.02. | MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | 1 | GlobeNewswire (USA) | ||
| 08.01. | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | 365 | GlobeNewswire (Europe) | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,80 | +0,06 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| BB BIOTECH | 49,700 | -0,60 % | Aktien KW 17 Märkte im Würgegriff. Planloser Trump , selbstbewusterer Iran. Lösungen müssen her. News. Rheinmetall. ITM Power. Porsche. The Platform Group. K+S. Bugatti. Circus. Surteco. NanoRepro. BB Biotech. Mensch und Maschine. ATOSS. MHP Hotel | Aktien - letzte Woche warteten die Märkte auf eine Lösung des Iran-Kriegs. Aber die Iraner sehen sich im Vorteil und Trump verlängert "auf unbestimmte Zeit" den Waffenstillstand. Aber die Strasse von... ► Artikel lesen | |
| VALNEVA | 2,579 | +1,02 % | Valneva senkt Prognose und baut Stellen ab | Beim Impfstoffspezialisten Valneva SE häufen sich im ersten Quartal 2026 die Belastungen: Der Nettoverlust weitete sich auf 32,1 Millionen Euro nach 9,2 Millionen Euro im Vorjahr aus, das bereinigte... ► Artikel lesen | |
| NOVAVAX | 7,770 | -1,52 % | Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes | ||
| OCUGEN | 1,222 | -2,40 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,100 | 0,00 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 2,166 | +0,46 % | Aktien im Fokus - Heidelberger Druck: Neue Rallye? - InflaRx, Nel ASA, Nordex, TKMS und TUI | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,520 | -5,57 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| EDITAS MEDICINE | 2,480 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,206 | +0,02 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,100 | 0,00 % | Sarepta tumbles as its gene therapy sales decline further | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,100 | +0,59 % | PacBio: HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss | ||
| CARDIOL THERAPEUTICS | 1,152 | -1,20 % | Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ | ||
| GERON | 1,190 | -1,53 % | Geron Corporation: First Real-World Evidence Study of RYTELO (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 | ||
| BASILEA | 61,10 | +0,66 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,400 Euro und damit +3,70 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.